Marty Lefkowitz

3.8k total citations · 3 hit papers
25 papers, 2.5k citations indexed

About

Marty Lefkowitz is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Marty Lefkowitz has authored 25 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Epidemiology. Recurrent topics in Marty Lefkowitz's work include Cardiovascular Function and Risk Factors (15 papers), Heart Failure Treatment and Management (14 papers) and Cardiac pacing and defibrillation studies (5 papers). Marty Lefkowitz is often cited by papers focused on Cardiovascular Function and Risk Factors (15 papers), Heart Failure Treatment and Management (14 papers) and Cardiac pacing and defibrillation studies (5 papers). Marty Lefkowitz collaborates with scholars based in United States, United Kingdom and Netherlands. Marty Lefkowitz's co-authors include John J.V. McMurray, Michael R. Zile, Scott D. Solomon, Milton Packer, Burkert Pieske, Elisabeth Kraigher‐Krainer, Amil M. Shah, Adriaan A. Voors, Victor Shi and Toni Bransford and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Investigation.

In The Last Decade

Marty Lefkowitz

23 papers receiving 2.4k citations

Hit Papers

The angiotensin receptor neprilysin inhibitor LCZ696 in h... 2012 2026 2016 2021 2012 2013 2025 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
    2012 883 citations Scott D. Solomon, Michael R. Zile et al. The Lancet profile →
  2. Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction
    2013 527 citations Elisabeth Kraigher‐Krainer, Amil M. Shah et al. Journal of the American College of Cardiology profile →
  3. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
    2025 35 citations Alexander Peikert, Muthiah Vaduganathan et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marty Lefkowitz United States 13 2.1k 437 404 294 279 25 2.5k
Paola Gargiulo Italy 23 922 0.4× 274 0.6× 264 0.7× 382 1.3× 207 0.7× 73 1.6k
Natalia Pezzali Italy 12 2.0k 1.0× 164 0.4× 550 1.4× 280 1.0× 221 0.8× 17 2.3k
Wojciech Kosmala Poland 28 1.7k 0.8× 239 0.5× 526 1.3× 175 0.6× 273 1.0× 98 2.1k
Eiichi Akiyama Japan 26 1.3k 0.6× 530 1.2× 260 0.6× 346 1.2× 503 1.8× 96 2.3k
Bertil Andrén Sweden 24 1.8k 0.9× 253 0.6× 455 1.1× 236 0.8× 427 1.5× 56 2.3k
Richard B. Devereux United States 7 2.3k 1.1× 374 0.9× 515 1.3× 185 0.6× 267 1.0× 10 2.6k
Mauro Gori Italy 18 1.5k 0.7× 324 0.7× 258 0.6× 360 1.2× 207 0.7× 80 1.8k
Sylvie A. Ahn Belgium 21 1.1k 0.5× 492 1.1× 215 0.5× 223 0.8× 411 1.5× 75 1.9k
Mary Paranicas United States 17 2.0k 1.0× 415 0.9× 516 1.3× 203 0.7× 223 0.8× 23 2.4k
Arif Elvan Netherlands 35 5.0k 2.3× 261 0.6× 225 0.6× 225 0.8× 416 1.5× 134 5.3k

Countries citing papers authored by Marty Lefkowitz

Since Specialization
Citations

This map shows the geographic impact of Marty Lefkowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marty Lefkowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marty Lefkowitz more than expected).

Fields of papers citing papers by Marty Lefkowitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marty Lefkowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marty Lefkowitz. The network helps show where Marty Lefkowitz may publish in the future.

Co-authorship network of co-authors of Marty Lefkowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Marty Lefkowitz. A scholar is included among the top collaborators of Marty Lefkowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marty Lefkowitz. Marty Lefkowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kondo, Toru, Pooja Dewan, Akshay S. Desai, et al.. (2025). Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Circulation Heart Failure. 18(3). e011598–e011598. 2 indexed citations
2.
Chimura, Misato, Jawad H. Butt, Shingo Matsumoto, et al.. (2025). Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM‐HF. Journal of the American Heart Association. 14(9). e038249–e038249. 1 indexed citations
3.
Peikert, Alexander, Muthiah Vaduganathan, Brian Claggett, et al.. (2025). Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. European Heart Journal. 46(25). 2372–2390. 35 indexed citations breakdown →
4.
Petrie, Mark C., Jean L. Rouleau, Brian Claggett, et al.. (2024). Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation. 149(4). 335–338. 1 indexed citations
5.
Gupta, Shruti, Jawad H. Butt, Atefeh Talebi, et al.. (2024). Effects of Sacubitril/Valsartan According to Background Beta-Blocker Therapy in Patients with Heart Failure and Reduced Ejection Fraction: Insights from PARADIGM-HF. European Journal of Heart Failure. 27(5). 779–787.
6.
Lu, Henri, Brian Claggett, Milton Packer, et al.. (2024). Sacubitril/Valsartan Reduces Incident Anaemia and Iron Therapy Utilization in Heart Failure: The PARAGON-HF Trial. European Journal of Heart Failure. 27(1). 85–95.
7.
Shen, Li, Brian Claggett, Pardeep S. Jhund, et al.. (2021). Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology. 110(8). 1334–1349. 5 indexed citations
8.
Jering, Karola, Brian Claggett, Margaret M. Redfield, et al.. (2021). Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy. JACC Heart Failure. 9(5). 386–397. 21 indexed citations
9.
Jering, Karola, Faı̈ez Zannad, Brian Claggett, et al.. (2020). CARDIOVASCULAR AND RENAL OUTCOMES OF MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PARAGON-HF. Journal of the American College of Cardiology. 75(11). 1030–1030. 6 indexed citations
10.
Yeoh, Su Ern, Pooja Dewan, Akshay S. Desai, et al.. (2020). Relationship Between Duration of Heart Failure, Patient Characteristics, Outcomes, and Effect of Therapy in PARADIGM-HF. ESC Heart Failure. 7(6). 3355–3364. 9 indexed citations
11.
Cunningham, Jonathan W., Brian Claggett, Eileen O’Meara, et al.. (2020). Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. Journal of the American College of Cardiology. 76(5). 503–514. 83 indexed citations
12.
Kristensen, Søren Lund, David Preiss, Pardeep S. Jhund, et al.. (2016). Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation Heart Failure. 9(1). 248 indexed citations
13.
Santos, Ângela Barreto Santiago, Elisabeth Kraigher‐Krainer, Deepak K. Gupta, et al.. (2014). Impaired Left Atrial Function in Heart Failure with Preserved Ejection Fraction. European Journal of Heart Failure. 16(10). 1096–1103. 194 indexed citations
14.
Gori, Mauro, Michele Senni, Deepak K. Gupta, et al.. (2014). Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal. 35(48). 3442–3451. 87 indexed citations
15.
Jhund, Pardeep S., Brian Claggett, Adriaan A. Voors, et al.. (2014). Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation Heart Failure. 7(6). 953–959. 67 indexed citations
16.
Santos, Ângela Barreto Santiago, Elisabeth Kraigher‐Krainer, Natalie A. Bello, et al.. (2013). Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. European Heart Journal. 35(1). 42–47. 53 indexed citations
17.
Kraigher‐Krainer, Elisabeth, Amil M. Shah, Deepak K. Gupta, et al.. (2013). Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 63(5). 447–456. 527 indexed citations breakdown →
18.
Solomon, Scott D., Michael R. Zile, Burkert Pieske, et al.. (2012). The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 380(9851). 1387–1395. 883 indexed citations breakdown →
19.
Chrysant, Steven G., Marty Lefkowitz, Thomas Salko, et al.. (2007). The effects of high‐dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Pressure. 16(sup1). 10–17. 11 indexed citations
20.
Mueller‐Lissner, Stefan, I. Fumagalli, Fábio Heleno de Lima Pace, et al.. (2000). Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS). Gastroenterology. 118(4). A175–A175. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Gargiulo Breakdown of academic impact, for papers by Natalia Pezzali Breakdown of academic impact, for papers by Wojciech Kosmala Breakdown of academic impact, for papers by Eiichi Akiyama Breakdown of academic impact, for papers by Bertil Andrén Breakdown of academic impact, for papers by Richard B. Devereux Breakdown of academic impact, for papers by Mauro Gori Breakdown of academic impact, for papers by Sylvie A. Ahn Breakdown of academic impact, for papers by Mary Paranicas Breakdown of academic impact, for papers by Arif Elvan
Rankless by CCL
2026